Suppliers and packagers for RYBELSUS

RYBELSUS

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-1704-30	30 TABLET in 1 BOTTLE, PLASTIC (0169-1704-30)	2026-02-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-1709-30	30 TABLET in 1 BOTTLE, PLASTIC (0169-1709-30)	2026-02-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-1715-30	30 TABLET in 1 BOTTLE, PLASTIC (0169-1715-30)	2026-02-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-1715-90	30 TABLET in 1 BOTTLE, PLASTIC (0169-1715-90)	2026-02-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4303-30	30 TABLET in 1 BOTTLE, GLASS (0169-4303-30)	2019-09-20
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051	NDA	Novo Nordisk	0169-4303-99	30 TABLET in 1 BOTTLE, GLASS (0169-4303-99)	2019-09-20

Rybelsus: Key Manufacturing Supply Chain Analysis

Last updated: February 19, 2026

Rybelsus (semaglutide oral tablets) is an orally administered glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes. The drug's approval in January 2020 marked a significant advancement in diabetes management, offering a non-injectable GLP-1 option. The manufacturing and supply chain for Rybelsus involve complex synthesis of the active pharmaceutical ingredient (API), semaglutide, and its formulation into oral tablets. Key suppliers are critical for ensuring the consistent availability and quality of the drug.

What is the Active Pharmaceutical Ingredient (API) for Rybelsus?

The active pharmaceutical ingredient in Rybelsus is semaglutide. Semaglutide is a peptide analogue of human GLP-1, modified to resist degradation in the body and prolong its half-life. Its synthesis is a multi-step process requiring specialized chemical expertise and infrastructure.

• Chemical Structure: Semaglutide is a modified peptide with a molecular weight of approximately 3150 Da. It comprises 31 amino acids, with modifications including acylation and albumin binding to extend its duration of action.
• Synthesis Complexity: Peptide synthesis, especially for large and modified peptides like semaglutide, is a technically demanding process. It typically involves solid-phase or liquid-phase peptide synthesis, followed by purification and modification steps.
• Manufacturing Location: Novo Nordisk is known to manufacture semaglutide API at its facility in Kalundborg, Denmark [1]. This integrated approach allows for close control over API quality and production volumes.

Who Manufactures Semaglutide API?

Novo Nordisk is the primary manufacturer of semaglutide API for Rybelsus. The company has invested heavily in its peptide manufacturing capabilities.

• Internal Manufacturing: Novo Nordisk maintains significant in-house API production capacity for semaglutide. This strategy is common for blockbuster drugs, providing greater control over supply chain security, intellectual property, and cost.
• Specialized Facilities: The Kalundborg facility is a major hub for Novo Nordisk's API production, including fermentation and chemical synthesis of peptides and insulin analogues [1].

What are the Key Excipients in Rybelsus Tablets?

Rybelsus tablets contain several inactive ingredients (excipients) that are crucial for tablet formation, stability, and absorption. These excipients are sourced from various specialized chemical manufacturers.

• Absorption Enhancer: A unique aspect of Rybelsus is its oral delivery technology, which requires a specific absorption enhancer to facilitate semaglutide's passage through the gastrointestinal tract. This is often attributed to sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC).
  • SNAC: SNAC is a well-known permeation enhancer used to improve the oral bioavailability of peptide drugs. Its inclusion is essential for the efficacy of oral semaglutide. Novo Nordisk has patented specific formulations involving SNAC and semaglutide [2].
• Other Excipients: Standard excipients found in oral solid dosage forms are also present, including:
  • Binders: Agents that hold the tablet ingredients together.
  • Disintegrants: Agents that help the tablet break apart in the digestive system.
  • Lubricants: Agents that prevent sticking to manufacturing equipment.
  • Fillers/Diluents: Agents that add bulk to the tablet.

Who Supplies Excipients for Rybelsus?

The suppliers of excipients for Rybelsus are typically large, well-established chemical companies that specialize in pharmaceutical-grade ingredients. While specific supplier contracts are proprietary, the types of companies involved can be identified.

• SNAC Suppliers: The primary supplier of SNAC is likely a company with advanced chemical synthesis capabilities for specialty ingredients. Companies like DistiNova have been associated with the development and supply of absorption enhancers for oral peptide delivery, though direct confirmation of their role with Rybelsus requires specific contractual disclosure. Adare Pharma Solutions is another company known for its expertise in drug delivery technologies and excipient development, including permeation enhancers.
• General Excipient Suppliers: For other common excipients, suppliers would include major global pharmaceutical ingredient manufacturers such as:
  • Roquette: A leading producer of plant-based ingredients, including binders and fillers like microcrystalline cellulose.
  • Ashland: Offers a wide range of excipients, including binders, disintegrants, and coatings.
  • BASF: A major chemical company with a significant pharmaceutical ingredients division, providing various excipients.
  • Evonik Industries: Supplies excipients for drug formulation, including polymers and lipids.

What are the Key Technologies in Rybelsus Manufacturing?

The manufacturing of Rybelsus relies on advanced pharmaceutical technologies, particularly for API synthesis and oral dosage form development.

• Peptide Synthesis: The synthesis of semaglutide utilizes sophisticated peptide synthesis techniques, likely including solid-phase peptide synthesis (SPPS) or hybrid approaches, followed by rigorous purification using chromatography. Novo Nordisk's internal expertise in biotechnology and chemical synthesis is a core competency.
• Oral Delivery Technology: The critical innovation for Rybelsus is its oral delivery system. This involves:
  • SNAC Formulation: The integration of SNAC with semaglutide is designed to protect the peptide from enzymatic degradation in the GI tract and enhance its absorption across the intestinal epithelium. Specific patent filings detail the composition and manufacturing processes involving SNAC [2].
  • Tablet Compression: Standard tablet compression technology is employed to form the final oral dosage form, ensuring uniformity in weight, hardness, and disintegration time.
• Quality Control: Advanced analytical techniques are employed throughout the manufacturing process to ensure the purity, potency, and stability of both the API and the finished drug product. This includes HPLC, mass spectrometry, and other pharmacopeial methods.

How is the Supply Chain for Rybelsus Managed?

Novo Nordisk manages the Rybelsus supply chain through a combination of internal production and strategic partnerships, emphasizing supply chain security and quality assurance.

• Integrated Supply Chain: Novo Nordisk’s strategy for high-value biologics and complex small molecules often involves a high degree of vertical integration. This is particularly evident in the production of semaglutide API at its Kalundborg facility.
• API Production: The bulk of semaglutide API is produced internally, mitigating risks associated with external API suppliers for such a critical and proprietary molecule.
• Finished Dosage Form (FDF) Manufacturing: While API is primarily internal, the formulation and manufacturing of the finished Rybelsus tablets may involve contract manufacturing organizations (CMOs) or be consolidated at Novo Nordisk’s own global FDF manufacturing sites. Novo Nordisk has manufacturing facilities in multiple locations, including Chartres, France, and Hillerød, Denmark, which could be involved in FDF production.
• Excipient Sourcing: Excipients are sourced from qualified global suppliers who meet stringent pharmaceutical quality standards (e.g., GMP compliance, ISO certifications). Supply agreements are established to ensure consistent quality and availability.
• Logistics and Distribution: A robust logistics network ensures timely distribution of the finished product to global markets, adhering to specific temperature and handling requirements to maintain product integrity.

What are the Regulatory Considerations for Rybelsus Suppliers?

Suppliers to the Rybelsus manufacturing process must adhere to strict regulatory requirements to ensure patient safety and product quality.

• Good Manufacturing Practices (GMP): All suppliers of APIs and excipients must operate under current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous process controls, documentation, and quality management systems.
• Drug Master Files (DMFs): Suppliers of APIs and certain critical excipients often submit Drug Master Files to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the drug substance or excipient, allowing regulatory authorities to review them during the drug approval process.
• Audits and Inspections: Novo Nordisk conducts regular audits of its suppliers to verify compliance with cGMP and contractual obligations. Regulatory agencies also perform inspections of these facilities.
• Change Control: Any changes to a supplier's manufacturing process, site, or specifications must be managed through a formal change control process, which often requires Novo Nordisk's and potentially regulatory authority's approval to ensure no adverse impact on the final drug product.

What is the Impact of Supply Chain on Rybelsus Availability?

The complex nature of Rybelsus manufacturing and its growing demand present ongoing challenges and opportunities for supply chain management.

• Increasing Demand: Rybelsus has seen significant demand growth globally, driven by its efficacy in type 2 diabetes management and its unique oral formulation. This rapid increase strains manufacturing capacity.
• Capacity Expansion: Novo Nordisk has announced substantial investments in expanding its manufacturing capacity for semaglutide, both for injectable formulations (Ozempic, Wegovy) and oral Rybelsus. This includes building new facilities and expanding existing ones in Denmark and elsewhere.
• API and Excipient Lead Times: The multi-step synthesis of semaglutide and the specialized nature of certain excipients can lead to long lead times. Securing sufficient API and high-quality excipients is critical to meeting demand.
• Geopolitical and Environmental Risks: Like all global supply chains, Rybelsus is susceptible to disruptions from geopolitical events, natural disasters, and environmental regulations, which can affect raw material availability and logistics.
• Strategic Sourcing: Novo Nordisk's reliance on internal API manufacturing for semaglutide provides a degree of supply chain resilience. However, the broader network of excipient suppliers and CMOs requires careful management and diversification where possible.

Key Takeaways

• Rybelsus's active pharmaceutical ingredient is semaglutide, primarily manufactured internally by Novo Nordisk at its Kalundborg, Denmark facility.
• A critical excipient is SNAC, a permeation enhancer essential for oral semaglutide absorption, sourced from specialized chemical manufacturers.
• General excipients are sourced from major global pharmaceutical ingredient suppliers adhering to stringent quality standards.
• Novo Nordisk employs advanced peptide synthesis and oral drug delivery technologies, with a strong emphasis on integrated supply chain management.
• Suppliers must comply with rigorous cGMP regulations, and regulatory filings like DMFs are integral to the supply chain's oversight.
• Growing global demand for Rybelsus necessitates continuous capacity expansion and robust supply chain management to ensure product availability.

Frequently Asked Questions

What is the primary manufacturing site for Rybelsus API?

The primary manufacturing site for semaglutide API used in Rybelsus is Novo Nordisk's facility in Kalundborg, Denmark.

Is SNAC synthesized by Novo Nordisk or outsourced?

While Novo Nordisk utilizes SNAC extensively in Rybelsus, the synthesis of this specialized excipient is typically outsourced to dedicated chemical manufacturing partners.

How does Novo Nordisk ensure the quality of its Rybelsus excipient suppliers?

Novo Nordisk ensures supplier quality through rigorous qualification processes, regular audits, and strict adherence to cGMP standards. They also establish detailed quality agreements with each supplier.

What are the potential risks to the Rybelsus supply chain?

Potential risks include disruptions to raw material sourcing, manufacturing capacity limitations due to high demand, logistical challenges, geopolitical instability, and regulatory changes affecting suppliers.

Does Novo Nordisk use contract manufacturing organizations (CMOs) for Rybelsus production?

Novo Nordisk maintains significant in-house manufacturing for semaglutide API and may utilize CMOs for specific steps in finished dosage form manufacturing or for certain excipient components, though their primary strategy for key components is often internal.

What are the regulatory requirements for API and excipient suppliers for Rybelsus?

Suppliers must comply with cGMP, provide necessary documentation (e.g., DMFs), undergo audits by Novo Nordisk and regulatory agencies, and adhere to strict change control procedures.

Citations

[1] Novo Nordisk. (n.d.). Our manufacturing facilities. Retrieved from https://www.novonordisk.com/about-novo-nordisk/our-business/manufacturing.html

[2] Novo Nordisk A/S. (2013). Pharmaceutical composition comprising a GLP-1 receptor agonist and an absorption enhancer. (WO 2013/007570 A1). World Intellectual Property Organization.